NEW YORK (GenomeWeb News) – Cancer Genetics today announced it has reached a deal with a second preferred provider organization.

The Rutherford, NJ-based firm has executed an agreement with Three Rivers Provider Network, providing about 15 million of the PPO's members access to Cancer Genetics' testing menu. The deal follows an agreement that Cancer Genetics inked with MultiPlan in May 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.